AzTrials
AzTrials

HypertensionPhase 1/2NCT02104375

L-citrulline Supplementation, Cold Exposure, & Post-Exercise Muscle Ischemia

A Phase 1/2 study testing L-citrulline in people with Hypertension, run by Florida State University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cardiovascular disease (CVD) continues to be the major cause of morbidity and mortality in western countries. It has been shown that CVD events are known to be higher in the winter than in the summer. Read more about this study

Who is it for?
Ages 18 to 35 years, men onlyHealthy volunteers can take part
Conditions the study is for
Hypertension
What is being tested?
L-citrulline
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
16 participants
Where
1 siteUnited States
Study dates
Mar 2013to Dec 2014
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Men
  • Blood pressure lower than 140/90mmHg
  • Age 18 to 35 years
  • BMI 25-39 kg/m2

Who cannot join

  • Blood Pressure >160/100 mmHg
  • Asthma
  • Glaucoma
  • Herpes simplex
  • Uncontrolled diabetes
  • Neurological disease
Show all 18Show fewer
  • Cardiovascular disease
  • Inflammatory disease
  • Kidney disease
  • Hormone replacement therapy (HRT)
  • Amino acid/vitamin supplementation\
  • Corticosteroids or non-steroidal anti-inflammatory drugs
  • Any drug known to affect BP or heart rate
  • Glycemic control drugs
  • Lipids reducing drugs
  • Participants should not consume > 12 alcoholic drink/week
  • Smokers
  • Regular Exercisers (>1.5 hour/week).

Trial locations and contacts

1 site in 1 country.

United States1 site
  • FSU College of Human Sciences

    Tallahassee, Florida, 32306

Other trials in United States

About this study

Official title: The Effects of L-Citrulline Supplementation on Vascular and Cardiac Autonomic Responses to Cold Pressor Test Concurrent With Postexercise Muscle Ischemia

Cardiovascular disease (CVD) continues to be the major cause of morbidity and mortality in western countries. It has been shown that CVD events are known to be higher in the winter than in the summer. Low environmental temperatures may induce increased cardiovascular stress resulting in cold-induced hypertension (CIH), the leading risk factor for CVD events. Similar to whole-body cold exposure, the cold pressor test (CPT), an external local cold stimulus, has been used for evaluation of cardiovascular and hemodynamic reactivity to sympathetic stimulation. It has been shown that brachial blood pressure (BP), pressure pulse wave reflection, aortic BP, heart rate (HR), and arterial stiffness are increased during CPT. However, the physiologic mechanisms for the cardiovascular complications related to low temperatures are not completely clear.

Isometric-handgrip (IHG) exercise has been used as a tool for assessing cardiovascular autonomic control by a maneuver defined as post-exercise muscle ischemia (PEMI). PEMI induces exercise pressor reflex (metaboreflex) by trapping metabolites in the previous active muscle at the cessation of exercise. During PEMI, the accumulation of contraction-derived metabolites induces sympathetic mediated vascular stimulation and an increased BP, whereas the HR fully recovers. This suggests that the fall in HR is evoked by an increase in parasympathetic activity which overpowers the sympathetic activation. Implication of IHG exercise followed by PEMI provides important clinical information because impaired autonomic and cardiovascular functions are associated with cardiovascular events.

Recently, oral supplementation with the amino acid L-citrulline (L-cit) has been proposed as a possible adjunct treatment for hypertension and arterial stiffness. L-cit is known to enhance the bioavailability of L-arginine (L-arg), the endothelial substrate for nitric oxide (NO) production. Cold exposure might include a temperature-dependent inhibition of endothelial NO synthase (eNOS), the enzyme that produces NO from the amino acid L-arg and may trigger various types of CVD. It has been shown that L-cit supplementation has effectively attenuated the CIH response during cold pressor test. Thus, L-cit supplementation may be effective to reduce the cardiovascular responses associated with cold exposure and the exercise pressor reflex imposed by PEMI. Therefore, the proposed study is important for the following reasons: (1) the results of his study will add to our understanding regarding the cardiovascular and autonomic mechanisms associated with exercise and cold exposure; (2) the results of this study will contribute to the development of an adjunct therapy for the prevention of cardiovascular adverse events that are particularly increased during stress such as cold exposure and exercise.

Read the detailed description

Specific Aims

AIM 1: To determine the acute effects of the exercise pressor response imposed by PEMI with and without CPT on hemodynamics and cardiac autonomic regulation in health overweight/obese men.

AIM 2: To examine the effects of a 14-day course of L-cit supplementation on arterial stiffness, aortic hemodynamics, and autonomic regulation at rest and during conditions characterized by increased sympathetic activity (IHG, PEMI, and PEMI concurrent with CPT).

Research Hypotheses

Hypothesis 1: There will be greater increases in peripheral and central BP, arterial stiffness, wave reflection, and cardiac sympathetic activity during PEMI concurrent with CPT than during PEMI alone.

Hypothesis 2: 14 days of L-cit supplementation will attenuate peripheral and central BP, wave reflection, arterial stiffness, and cardiac sympathetic activity responses during IHG exercise, PEMI, and PEMI concurrent with CPT compared with placebo (PL) supplementation.

Description of the study

A total of twenty male young adults (18-35 years) with overweight or obesity [body mass index (BMI) >25 and <40 kg/m2] will be enrolled in this study. All of the subjects will be nonsmokers, no L-cit or L-arg users or regular exercisers (defined as more than 120 min per week) at least 6 months before the study begins. Subjects will be asked to maintain their diet and exercise habits during the study period.

Study design:

After completion of initial screening, cardiovascular and autonomic function of eligible subjects will be evaluated in a quiet temperature-controlled room (22-24°C). After baseline measurement, in a cross-over design fashion, subjects will be randomized to either Placebo group (Maltodextrin) or L-citrulline group for the first 14 days of the study that will be followed by a 14 day washout period and then will be crossed over to their next treatment. Cardiovascular function will be evaluated at baseline and after 14 days of the first and the second treatment. Measurements will be conducted in the morning after at least 8 hours of an overnight fast in order to avoid potential diurnal variations in BP and vascular reactivity.

Conditions
Hypertension
Being tested
L-citrulline
Keywords
wave reflection, augmentation Index, heart rate variability, arterial stiffness
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • L-citrullineDietary supplement

    Also called 2 weeks of L-citrulline supplementation (6g/day).

    2 weeks of L-citrulline supplementation (6g/day).

Study groups in NCT02104375
Study groupRoleWhat they receive
L-citrullineExperimentalL-citrulline (6 g/day for 2 weeks)
Receives: Dietary Supplement: L-citrulline
MaltodextrinPlacebo comparator6g/day of placebo (maltodextrin)
Receives: Dietary Supplement: L-citrulline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Blood Pressure

    By measuring brachial and central (aortic and carotid) BP at rest and during physiological stress (cold pressor test, post-exercise muscle ischemia, and handgrip test)

    Measured: 6 weeks

Secondary outcomes (1)
  1. Arterial Stiffness

    By measuring brachial-ankle pulse wave velocity at rest and during physiological stress (cold pressor test, post-exercise muscle ischemia, and handgrip test)

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Apr 2014 (estimated)
  2. Study startMar 2013
  3. Primary completionDec 2013
  4. Study completionDec 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02104375
Sponsor's protocol ID
2013.11742
Status last verified
Mar 2015
First submitted
2 Apr 2014
Last updated
10 Mar 2015
Results posted
No
Data monitoring committee
No

Publications

  • Kalfon R, Campbell J, Alvarez-Alvarado S, Figueroa A. Aortic Hemodynamics and Arterial Stiffness Responses to Muscle Metaboreflex Activation With Concurrent Cold Pressor Test. Am J Hypertens. 2015 Nov;28(11):1332-8. doi: 10.1093/ajh/hpv043. Epub 2015 Apr 22.

    PubMed 25904650

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing L-citrulline in people with Hypertension, run by Florida State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Blood Pressure (time frame: 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02104375, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in